View DividendThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharmasimple 경영진경영진 기준 점검 0/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보Michael Willems최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간10.3yrsCEO 지분 보유율n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간2.5yrs최근 경영진 업데이트Board Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.모든 업데이트 보기Recent updatesBoard Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.공시 • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.분석 기사 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).분석 기사 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.분석 기사 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.CEOMichael Willems 10.3yrs재임 기간Mr. Michaël Willems has been the Chief Executive Officer and Chairman of Pharmasimple SA since October 31, 2013.이사회 구성원이름직위재임 기간보수지분Michael WillemsChairman & CEO10.3yrs데이터 없음데이터 없음Annabelle-Thiry WillemsCo-Founder & Director2.8yrs데이터 없음데이터 없음Didier PetreDirector2.3yrs데이터 없음데이터 없음Harold LannoyDirector2.3yrs데이터 없음데이터 없음더 보기2.5yrs평균 재임 기간경험이 풍부한 이사회: ALPHS의 이사회는 경험이 부족한 것으로 간주됩니다(평균 재임 2.5 년) — 신규 이사회일 가능성이 있습니다.View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/09 16:12종가2024/02/09 00:00수익2021/06/30연간 수익2020/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmasimple SA는 1명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Florent Thy-TineTPICAP Midcap
Board Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.
공시 • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.
분석 기사 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...
Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.
Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.
Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.
Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).
분석 기사 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.
분석 기사 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.